Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Jacob George , Thomas M MacDonald Added: 3 years ago
Hypertension increases the risk of heart attack, stroke, kidney disease, and heart failure1 and is the leading preventable risk factor for global cardiovascular (CV) disease burden worldwide.2 At ages 40–69 years, each increase of 20 mmHg in systolic blood pressure (BP) is associated with more than a doubling of the baseline mortality rate from cardiovascular disease (CVD).3 However, despite the… View more
Author(s): Robert H Fagard Added: 3 years ago
After the initial investigations by Perloff et al.,1 our knowledge of the prognostic significance of ambulatory blood pressure (ABP) measurements has considerably increased. There is currently little doubt that 24-hour ABP is a better predictor of mortality and morbidity than conventional or office blood pressure (BP). This has been shown in the general population, in elderly, in treated and… View more
Research Area(s) / Expertise: Job title: Chairman of the Department of Clinical Medicine and Prevention
Giuseppe Mancia is Professor Emeritus at the University Milano-Bicocca, after serving for 20 years as Chairman of the Division and Department of Internal Medicine at the same university at the San Gerardo Hospital in Monza and Director of the Interuniversity (Universities of Milano, Milano-Bicocca, and Pavia) Center for Clinical Physiology and Hypertension. He was Chairman (2001, 2003, 2005, 2007… View more
Author(s): Giuseppe Mancia Added: 3 years ago
The attitude to modern antihypertensive treatment differs from that which prevailed only a few years ago in several important aspects. First, conclusive evidence is now available demonstrating that, since a substantial fraction of the benefit associated with antihypertensive treatment depends on blood-pressure lowering per se,1 reducing elevated blood pressure to <140/90mmHg is beneficial no… View more
Author(s): Thomas Kahan Added: 3 years ago
High blood pressure is the major risk factor for disease and premature death worldwide.1 The associations between blood pressure and fatal coronary artery disease and fatal stroke have been well demonstrated.2 Also, associations between blood pressure and morbidity and mortality on specific cardiovascular disease conditions in different age groups, and results concerning the lifetime risk for… View more
Author(s): George L Bakris , Sukriti Banthiya Added: 5 months ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients… View more
Author(s): Markus P Schlaich Added: 1 year ago
AHA 2022 — Dr Markus P Schlaich (University of Western Australia, AU) joins us to discuss the key findings from the PRECISION trial (NCT03541174).This randomized, phase 3 study assessed the sustained blood pressure lowering effect of a dual endothelin receptor antagonist, aprocitentan (Idorsia Pharmaceuticals Ltd.) in resistant hypertension. Presented first at AHA 22, the trial showed that… View more
Author(s): Francesco P Cappuccio Added: 3 years ago
Hypertension is a major independent risk factor for cardiovascular (CV) diseases, including cardiac death, coronary heart disease, heart failure, stroke and chronic kidney disease. Therefore, early diagnosis, prevention and optimal management of hypertension is essential.1 Hypertension poses a growing public health burden: the number of adults with elevated blood pressure (BP) increased from 594… View more
Author(s): E Ahsanova , V Popov , N Bulanova , et al Added: 3 years ago
Objective: To evaluate the efficacy and safety of melatonin therapy in hypertensive patients based on the assessment of daily blood pressure monitoring. Materials and methods: 30 men with arterial hypertension aged from 27 to 58 years, mean age 45.5 ± 9.2 years, were included in the study. Daily ambulatory blood pressure monitoring with a portable BR-102 Plus blood pressure registrar (Schiller)… View more
Author(s): Alexandre Persu , Fadl Elmula M Fadl Elmula , Yu Jin , et al Added: 3 years ago
Renal sympathetic denervation (RDN) has been introduced as a novel approach to treat patients with so-called resistant hypertension.1–3 The first randomised clinical trial showed an impressive 32/12 mmHg fall in blood pressure after six months in the intervention group (n=52) compared to the control group (n=54). However, with the recent publication of the Symplicity HTN-3 study in the US4 the… View more